New Oral Anticoagulants: Benefit-Risk Profile, Recurrence Rates, and Long-term Complications in Patients Treated for Established VTE
Clinical Pulmonary Medicine, 05/02/2012
Tapson V – New oral anticoagulants that do not require injections, routine coagulation monitoring, dose adjustment, or food restrictions are currently in development and/or recently approved and may enable physicians to better control anticoagulation therapy. Several Phase III trials have reported that the direct Factor Xa inhibitors rivaroxaban and apixaban and the direct thrombin inhibitor dabigatran are as effective as or superior to currently used low–molecular weight heparins or vitamin K antagonists.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.